Pure Global

Nasal Spray - Vietnam Registration 240000003/PCBA-HN

Access comprehensive regulatory information for Nasal Spray in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại A medical device is registered under number 240000003/PCBA-HN and manufactured by International Pharmaceutical Co., Ltd. Thăng Long. The authorized representative in Vietnam is CÔNG TY CỔ PHẦN DƯỢC PHẨM QUỐC TẾ THĂNG LONG.

This page provides complete technical specifications, regulatory compliance details, 5 companies making similar products including ÉLOGE FRANCE VIETNAM PHARMACEUTICAL JOINT VENTURE JOINT STOCK COMPANY, Church& Dwight UK Ltd, and 5 recent registrations in the same category. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
5 Competitors
5 Recent Registrations
240000003/PCBA-HN
Registration Details
Vietnam MOH Registration: 240000003/PCBA-HN
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Nasal Spray
VN: Xịt xoang
Risk Class TTBYT Loại A

Registration Details

240000003/PCBA-HN

000.00.19.H26-231229-0028

Hai Sen

Company Information

CÔNG TY CỔ PHẦN DƯỢC PHẨM QUỐC TẾ THĂNG LONG

Technical Details

- It helps to keep the nasal passages clean, thin out the mucus, remove the dirt from the nasal cavity, maintain the moisture of the nasal mucosa, and make the nose more breathable. - It supports the prevention and reduction of symptoms: runny nose, sneezing, nasal congestion, itchy nose, runny nose, rhinitis, acute and chronic sinusitis, allergic rhinitis, frontal sinusitis causing headaches, ... It reduces the accumulation of mucus, and enhances the resistance of the nasal mucosa. - It helps to clear the airways, reduce inflammation and swelling of the nasal mucosa, reduce swelling (polyps) in the nose, reduce the irritation of the nasal cavity, and address the problem of damaged mucosa (mucosal regeneration).

Dates and Status

Jan 02, 2024